Update in Antifungal Therapy of Dermatophytosis

Loo DS. Systemic antifungal agents: an update of established and new therapies. Adv Dermatol. 2006;22:101–24. Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R. Treatment options—development of consensus guidelines. J Eur Acad Dermatol Venereol. 2005;19(Suppl 1):25–33. TARO Pharmaceuticals Inc. Clotrimazole cream USP, 1%. Prescribing information. Bramalea, Ontario, Canada, June 1996. TARO Pharmaceuticals Inc. Econazole nitrate cream 1%. Prescribing information. Brampton, Ontario, Canada, September 2001. Merz Pharmaceuticals. Naftin® Naftifine HCl 1% gel/cream. Prescribing information. Greensboro, NC, USA, May 2007. McNeil Consumer & Specialty Pharmaceuticals. Nizoral® (ketoconazole) 2% shampoo. Prescribing information. Fort Washington, PA, USA, October 2003. TARO Pharmaceuticals Inc. Ciclopirox olamine cream USP, 0.77%. Prescribing information. Brampton, Ontario, Canada, March 2005. MEDICIS, The Dermatology Company. Loprox® Gel (ciclopirox) 0.77%. Prescribing information. Scottsdale, AZ, USA, July 2005. BERTEK Pharmaceuticals Inc. Mentax®-TC (butenafine HCl) cream, 1%. Prescribing information. Research Triangle Park, NC, USA, October 2002. GlaxoSmithKline Consumer Healthcare LP. Oxistat® (oxiconazole nitrate cream) cream 1%; Oxistat® (oxiconazole nitrate lotion) lotion 1%. Prescribing information. Pittsburgh, PA, USA, January 2004. Gupta AK, Chow M, Daniel CR, Aly R. Treatments of tinea pedis. Dermatol Clin. 2003;21:431–62. Lamisil® (terbinafine hydrochloride tablets) Prescribing information. Novartis Pharmaceuticals Corporation. East Hanover, NJ, November 2005. Sporanox® (itraconazole) Capsules prescribing information (Ortho-McNeil Inc). Janssen Pharmaceutica Products, L.P. Titusville, NJ, June 2006. Diflucan® (fluconazole tablets) (fluconazole injection—for intravenous infusion only) (fluconazole for oral suspension) Prescribing information. Pfizer Inc, August 2004. Griseofulvin (Systemic). In: Drug information for the health care professional, USP DI, The United States Pharmacopeial Convention, Inc., ed 24, Taunton MA, 2004, Micromedex, p. 1493–6. Miscellaneous Antifungals—Griseofulvin. In: AHFS Drug Information® 2005. Bethesda, MD, 2005, American Society of Health-System Pharmacists, Inc., p. 535–7. Azoles—Ketoconazole. In: AHFS Drug Information® 2005. Bethesda, MD, 2005, American Society of Health-System Pharmacists, Inc., p. 510–6. Gupta AK, Cooper EA, Montero-Gei F. The use of fluconazole to treat superficial fungal infections in children. Dermatol Clin. 2003;21:537–42. Gupta AK, Cooper EA, Ginter G. Efficacy and safety of itraconazole use in children. Dermatol Clin. 2003;21:521–35. Gupta AK, Cooper EA, Lynde CW. The efficacy and safety of terbinafine in children. Dermatol Clin. 2003;21:511–20. Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin. 2003;21:469–79. Antifungals, Azole (Systemic). In: Drug information for the health care professional, USP DI, The United States Pharmacopeial Convention, Inc., ed 24, Taunton MA, 2004, Micromedex. p. 315–23. Padhye AA, Weitzman I. The dermatophytes. In: Collier L, Balows A, Sussman M, Ajello L, Hay RJ, editors. Topley and Wilson’s medical mycology. New York: Oxford University Press; 1998. p. 215–36. Noble SL, Forbes RC, Stamm PL. Diagnosis and management of common tinea infections. Am Fam Physician. 1998;58:163–8. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001434. Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol. 2004;5:225–37. Crawford F. Athlete’s foot. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, editors. Evidence based dermatology. London: BMJ Books; 2003. p. 436–40. Gupta AK, Chaudhry M, Elewski B. Tinea corporis, tinea cruris, tinea nigra, and piedra. Dermatol Clin. 2003;21:395–400. Gupta AK, De Doncker P, Heremans A, et al. Itraconazole for the treatment of tinea pedis: a dose of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J Am Acad Dermatol. 1997;36:789–92. Faergemann J, Mork NJ, Haglund A, et al. A multicentre (double-blind) comparative study to assess the safety and efficacy of fluconazole and griseofulvin in the treatment of tinea corporis and tinea cruris. Br J Dermatol. 1997;136:575–7. Stary A, Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology. 1998;196:237–41. Suchil P, Montero Gei F, Robles M, et al. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Clin Exp Dermatol. 1992;17:397–401. Haroon TS, Asghar HA, Aman S, et al. An open, non-comparative study for the evaluation of oral fluconazole in the treatment of tinea corporis. Specialist. 1997;13:417–23. Papini M, Difonzo EM, Cilli P, et al. Itraconazole versus fluconazole, a double-blind comparison in tinea corporis. J Mycol Méd. 1997;7:77–80. Kotogyan A, Harmanyeri Y, Tahsin Gunes A, et al. Efficacy and safety of oral fluconazole in the treatment of patients with tinea corporis, cruris or pedis or cutaneous candidiasis. A multicentre, open, non-comparative study. Clin Drug Investig. 1996;12:59–66. Gomez M, Arenas R, Salazar JJ, et al. Tinea pedis. A multicentre trial to evaluate the efficacy and tolerance of a weekly dose of fluconazole. Dermatol Rev Mex. 1996;40:251–5 (Spanish). Del Aguila R, Montero Gei F, Robles M, et al. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea pedis. Clin Exp Dermatol. 1992;17:402–6. Gupta AK, Ryder JE, Chow M, Cooper EA. Dermatophytosis: the management of fungal infections. Skinmed. 2005;4:305–10. Trent JT, Federman D, Kirsner RS. Common viral and fungal skin infections. Ostomy Wound Manage. 2001;47:28–34. De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol. 1997;37:969–74. Parent D, Decroix J, Heenen M. Clinical experience with short schedules of itraconazole in the treatment of tinea corporis and/or tinea cruris. Dermatology. 1994;189:378–81. Gupta AK, Summerbell RC. Tinea capitis. Med Mycol. 2000;38:255–87. Roberts BJ, Friedlander SF. Tinea capitis: a treatment update. Pediatr Ann. 2005;34:191–200. Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol. 2002;146:816–23. Gupta AK, Skinner AR. Onychomycosis in children: a brief overview with treatment strategies. Pediatr Dermatol. 2004;21:74–9. Tosti A, Piraccini BM, Iorizzo M. Management of onychomycosis in children. Dermatol Clin. 2003;21:507–9. Chan Y, Friedlander SF. New treatments for tinea capitis. Curr Opin Infect Dis. 2004;17:97–103. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol. 1996;135:86–8. Friedlander SF, Aly R, Krafchik B, et al. Terbinafine in the treatment of Trichophyton tinea capitis: a randomized, double-blind, parallel-group, duration-finding study. Pediatrics. 2002;109:602–7. Lipozencic J, Skerlev M, Orofino-Costa R, et al. A randomized, double-blind, parallel-group, duration-finding study of oral terbinafine and open-label, high-dose griseofulvin in children with tinea capitis due to Microsporum species. Br J Dermatol. 2002;146:816–23. Gupta AK, Solomon RS, Adam P. Itraconazole oral solution for the treatment of tinea capitis. Br J Dermatol. 1998;139:104–6. Dastghaib L, Azizzadeh M, Jafari P. Therapeutic options for the treatment of tinea capitis: griseofulvin versus fluconazole. J Dermatolog Treat. 2005;16:43–6. Montero Gei F. Fluconazole in the treatment of tinea capitis. Int J Dermatol. 1998;37:870–1. Gupta AK, Dlova N, Taborda P, et al. Once weekly fluconazole is effective in the treatment of tinea capitis: a prospective, multicentre study. Br J Dermatol. 2000;142:965–8. Gupta AK, Scher RK. Management of onychomycosis: a North American perspective. Dermatol Ther. 1997;3:58–65. Gupta AK, Ryder J, Bluhm R. Onychomycosis. In: Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B, editors. Evidence based dermatology. London: BMJ Books; 2003. p. 441–68. Tavakkol A, Fellman S, Kianifard F. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in Onychomycosis-Concomitant Lamisil® and Debridement (IRONCLAD®), an open-label, randomized trial. Am J Geriatr Pharmacother. 2006;4:1–13. Potter LP, Mathias SD, Raut M, et al. The impact of aggressive debridement used as an adjunct therapy with terbinafine on perceptions of patients undergoing treatment for toenail onychomycosis. J Dermatolog Treat. 2007;18:46–52. Daniel CR III. Traditional management of onychomycosis. J Am Acad Dermatol. 1996;35:S21–5. King B. Pain at first dressing change after toenail avulsion: the experience of nurses, patients and an observer: 1. J Wound Care. 2003;12:5–10. Seebacher C, Brasch D, Abeck O, et al. Onychomycosis. Mycoses. 2007;50:321–7. Baran R, Hay RJ, Haneke E, Tosti A. Review of current antifungal treatment. Onychomycosis: the current approach to diagnosis and therapy. London: Martin Dunitz Ltd.; 1999. p. 44–69. Hay RJ, Baran R, Haneke E. Fungal (onychomycosis) and other infections involving the nail apparatus. In: Baran R, Dawber RPR, de Berker DAR, Haneke E, Tosti A, editors. Baran and Dawber’s diseases of the nails and their management. Osney Mead, Oxford: Blackwell Science Ltd.; 2001. p. 129–71. Grover C, Bansal S, Nanda S, et al. Combination of surgical avulsion and topical therapy for single nail onychomycosis: a randomized controlled trial. Br J Dermatol. 2007;157:364–8. Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2005;19:21–9. Penlac® Nail Lacquer (ciclopirox) Topical Solution, 8% Prescribing information. Dermik Laboratories (a division of Sanofi-Aventis). Bridgewater, NJ, July 2006. Gupta AK, Ryder JE, Skinner AR. Treatment of onychomycosis: pros and cons of antifungal agents. J Cutan Med Surg. 2004;8:25–30. Warshaw EM, St Clair KR. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol. 2005;53:717–20. Daniel CR, Gupta AK, Daniel MP, Daniel CM. Two feet-one hand syndrome: a retrospective multicenter survey. Int J Dermatol. 1997;36:658–60. Sigurgeirsson B, Elewski BE, Rich PA, et al. Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: a randomized, double-blind comparison. J Dermatolog Treat. 2006;17:38–44. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther. 2007;20:31–46. Olafsson JH, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol. 2003;149(Suppl 65):15–8. Evans EGV. Drug synergies and the potential for combination therapy in onychomycosis. Br J Dermatol. 2003;149(Suppl 65):11–3. Nandedkar-Thomas MA, Scher RK. An update on disorders of the nails. J Am Acad Dermatol. 2005;52:877–87. Gupta AK, Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol. 2005;4:481–5. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol. 2001;145(Suppl 60):15–9. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain. Br J Dermatol. 2001;145(Suppl 60):21–6. Binstock JM. Molecular biology techniques for identifying dermatophytes and their possible use in diagnosing onychomycosis in human toenails. J Am Podiatr Med Assoc. 2007;97:134–44. de Assis Santos D, de Carvalho Araujo RA, Kohler LM, et al. Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment. Int J Antimicrob Agents. 2007;29:563–9. Brillowska-Dabrowska A, Saunte DM, Arendrup MC. Five-hour diagnosis of dermatophyte nail infections with specific detection of Trichophyton rubrum. J Clin Microbiol. 2007;45:1200–4. Savin C, Huck S, Rolland C, et al. Multicenter evaluation of a commercial PCR-enzyme-linked immunosorbent assay diagnostic kit (Onychodiag) for diagnosis of dermatophytic onychomycosis. J Clin Microbiol. 2007;45:1205–10. Gupta AK, Zaman M, Singh J. Fast and sensitive detection of Trichophyton rubrum DNA from the nail samples of patients with onychomycosis by a double-round polymerase chain reaction-based assay. Br J Dermatol. 2007;157:698–703.